The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine
  • Phase

    Phase 4
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

To measure the magnitude and persistence of the antibody response to a booster dose of Hib conjugate vaccine given between 9 months and 4 years of age to UK children who had completed primary immunisation with 3 doses of Hib vaccine given at 2/3/4 months of age either as a combined D/T/wholecellpertussis/Hib or D/T/acellularpertussis/Hib vaccine.
Study Started
Apr 30
Primary Completion
Dec 31
Study Completion
Dec 31
Last Update
Aug 24

Biological Hib conjugate vaccine


Inclusion Criteria:

Written informed consent from parent or legal guardian of the infant or child
Age >= 9 months and <4 years at recruitment
Eligible to receive a single dose of Hib vaccine as per the UK schedule
Receipt of three doses of Hib vaccine in infancy

Exclusion Criteria:

History of Hib infection
History of severe local reaction that can be confidently related to a prior Hib immunisation
Deferral of vaccination if acute illness and/or temperature >38C on day of vaccination
No Results Posted